Enoxaparin Sodium Injection is a generic version of LOVENOX® (enoxaparin sodium injection), a low-molecular-weight heparin product widely used for the prevention and treatment of deep vein thrombosis (DVT).
Enoxaparin is a heterogeneous mixture of complex polysaccharide chains. The length and sequence of the polysaccharide chains that comprise enoxaparin vary in length and form, resulting in a diverse mixture of chemical structures and making it difficult to decipher. Our technology and analytical approach allowed us to characterize LOVENOX and successfully develop the first FDA approved generic version, which was approved in July 2010. In June 2018, Sandoz alerted the FDA and its customers that it will be discontinuing the supply of the Enoxaparin injection product.
LOVENOX® is a registered trademark of Sanofi-Aventis.
Last Updated 1/4/2016